Hani Gabra

List of Publications by Year
in descending order

68 papers	6,137 citations	159358 30 h-index	106150 65 g-index
69 all docs	69 docs citations	69 times ranked	11066 citing authors

#	Article	IF	Citations
1	Wholeâ€“genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	13.7	1,206
2	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	12.8	1,084
3	Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ: British Medical Journal, 2017, 356, j477.	2.4	539
4	Copy number signatures and mutational processes in ovarian carcinoma. Nature Genetics, 2018, 50, 1262-1270.	9.4	320
5	Risk factors for endometrial cancer: An umbrella review of the literature. International Journal of Cancer, 2019, 145, 1719-1730.	2.3	290
6	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology, 2011, 29, 3798-3804.	0.8	203
7	OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nature Genetics, 2003, 34, 337-343.	9.4	169
8	HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. Cancer Research, 2011, 71, 4412-4422.	0.4	159
9	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	6.3	142
10	Carcinosarcoma of the ovary. Cancer, 2004, 100, 2148-2153.	2.0	133
11	A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nature Communications, 2019, 10, 764.	5.8	130
12	Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ: British Medical Journal, 2017, 359, j4511.	2.4	107
13	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtypeâ€“specific therapeutic target for ovarian cancer. Science Signaling, 2016, 9, ra97.	1.6	105
14	Endometrioid epithelial ovarian cancer. Cancer, 2008, 112, 2211-2220.	2.0	89
15	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2017, 23, 2213-2222.	3.2	83
16	Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. Molecular Cancer Research, 2018, 16, 1103-1111.	1.5	83
17	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1 0.784314 rgBT /Over 541-553.	6.3	75
18	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 213, 123-139.	0.5	64

#	Article	IF	Citations
19	Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification . Journal of Pain Research, 2019, Volume 12, 2039-2052.	0.8	58
20	Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. Annals of Surgical Oncology, 2019, 26, 2943-2951.	0.7	54
21	Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews, 2013, 39, 153-160.	3.4	53
22	The OPCML Tumor Suppressor Functions as a Cell Surface Repressorâ€“Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer. Cancer Discovery, 2012, 2, 156-171.	7.7	50
23	The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates. Clinical Cancer Research, 2005, 11, 5764-5768.	3.2	49
24	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer, 2015, 51, 1978-1988.	1.3	44
25	Endocrine therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 109-117.	1.1	41
26	TRAP1 downregulation in human ovarian cancer enhances invasion and epithelialâ€“mesenchymal transition. Cell Death and Disease, 2016, 7, e2522-e2522.	2.7	40
27	The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. Oncotarget, 2015, 6, 31593-31603.	0.8	39
28	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. Journal of Clinical Oncology, 2017, 35, 587-590.	0.8	38
29	WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response. Cell Death and Disease, 2017, 8, e2955-e2955.	2.7	37
30	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. British Journal of Cancer, 2018, 119, 815-822.	2.9	35
31	Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. International Journal of Oncology, 2016, 49, 1651-1665.	1.4	34
32	Oncologist-led BRCA â€˜mainstreamingâ€™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports, 2020, 10, 3390.	1.6	34
33	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2017, 23, 7621-7632.	3.2	31
34	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO Reports, 2018, 19, .	2.0	30
35	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€“Innovative Models Prolong Survival (OCTIPS) Consortium. European Journal of Cancer, 2017, 79, 214-225.	1.3	29
36	Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy. Oncotarget, 2016, 7, 7216-7226.	0.8	29

#	Article	IF	Citations
37	Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. Cancer Research, 2003, 63, 8648-55.	0.4	29
38	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology, 2019, 293, 374-383.	3.6	25
39	Dose-Finding Quantitative ¹⁸F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. Journal of Nuclear Medicine, 2015, 56, 1828-1835.	2.8	24
40	The Tumor-Suppressor Protein OPCML Potentiates Antiâ€“EGFR- and Antiâ€“HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2246-2256.	1.9	24
41	Evaluation of 2-Deoxy-2-[18F]Fluoro-D-glucose- and 3â€²-Deoxy-3â€²-[18F]Fluorothymidineâ€“Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer. Molecular Imaging and Biology, 2012, 14, 753-761.	1.3	23
42	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23
43	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. British Journal of Cancer, 2017, 116, 1287-1293.	2.9	22
44	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget, 2015, 6, 41736-41749.	0.8	22
45	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nature Communications, 2021, 12, 1454.	5.8	20
46	The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. British Medical Bulletin, 2014, 112, 57-69.	2.7	19
47	Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 1524.	1.6	18
48	Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membraneâ€“Lipid Raft Interactions in Cancer. Journal of Proteome Research, 2016, 15, 3451-3462.	1.8	15
49	Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer Biology and Therapy, 2019, 20, 21-30.	1.5	14
50	The association between obesity and weight loss after bariatric surgery on the vaginal microbiota. Microbiome, 2021, 9, 124.	4.9	14
51	Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures. Modern Pathology, 2014, 27, 433-442.	2.9	13
52	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. British Journal of Cancer, 2018, 119, 330-338.	2.9	13
53	[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1239-1251.	3.3	12
54	Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population . Hepatic Medicine: Evidence and Research, 2019, Volume 11, 47-67.	0.9	10

#	Article	IF	Citations
55	Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. Nature Communications, 2019, 10, 3134.	5.8	9
56	The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer. Women's Health, 2015, 11, 355-367.	0.7	8
57	Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 133-147.	0.4	7
58	Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients. Scientific Reports, 2018, 8, 14695.	1.6	7
59	Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array. Translational Research, 2020, 218, 57-72.	2.2	7
60	ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2576-2576.	0.8	7
61	Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Cancer Gene Therapy, 2021, 28, 18-26.	2.2	6
62	ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2531-2531.	0.8	5
63	A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3028-3038.	3.2	4
64	Targeting the AKT Pathway in Ovarian Cancer. , 2011, , 73-94.		3
65	Epithelial Ovarian Cancer. , 2012, , 760-775.		2
66	A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5565-5565.	0.8	2
67	Epithelial Ovarian Cancer. , 0, , 625-635.		1
68	Current clinical trials in ovarian cancer. , 0, , 205-222.		0